LENZ Therapeutics Inc Cash Flow Conversion Efficiency
LENZ Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, LENZ Therapeutics Inc (LENZ) has a cash flow conversion efficiency ratio of -0.177x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-38.71 Million) by net assets ($219.26 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of LENZ Therapeutics Inc (2019–2025)
Cash flow conversion efficiency of LENZ Therapeutics Inc from 2019 to 2025. This chart illustrates how LENZ Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View LENZ Therapeutics Inc share price for real-time trading data and today's change.
LENZ Therapeutics Inc Cash Flow Conversion Ratio Explained
LENZ Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
LENZ Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of LENZ Therapeutics Inc ranked by their cash flow conversion efficiency. Also see LENZ Therapeutics Inc (LENZ) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Star Holdings
NASDAQ:STHO
|
-0.030x |
|
Organogenesis Holdings Inc
NASDAQ:ORGO
|
0.008x |
|
Fullerton Technology Co Ltd
TW:6136
|
0.007x |
|
Patriot National Bancorp Inc
NASDAQ:PNBK
|
-0.063x |
|
Seer Inc
NASDAQ:SEER
|
-0.042x |
|
AKA Brands Holding Corp
NYSE:AKA
|
-0.041x |
|
Technical Olympic S.A
AT:OLYMP
|
-0.002x |
|
Dekuple
PA:DKUPL
|
0.153x |
Annual Cash Flow Conversion Efficiency for LENZ Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of LENZ Therapeutics Inc from 2019 to 2025. Review LENZ Therapeutics Inc free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $284.34 Million | $-69.17 Million | -0.243x | +16.41% |
| 2024-12-31 | $204.08 Million | $-59.39 Million | -0.291x | -144.68% |
| 2023-12-31 | $-92.71 Million | $-60.38 Million | 0.651x | -82.11% |
| 2022-12-31 | $-24.17 Million | $-87.98 Million | 3.640x | -2.10% |
| 2021-12-31 | $-14.21 Million | $-52.85 Million | 3.718x | +317.84% |
| 2020-12-31 | $-9.80 Million | $-8.72 Million | 0.890x | +10288.39% |
| 2019-12-31 | $-2.22 Million | $-19.00K | 0.009x | -- |
About LENZ Therapeutics Inc
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2… Read more